Prescription of reninâ angiotensinâ aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care
dc.contributor.author | Pecoits‐filho, Roberto | |
dc.contributor.author | Fliser, Danilo | |
dc.contributor.author | Tu, Charlotte | |
dc.contributor.author | Zee, Jarcy | |
dc.contributor.author | Bieber, Brian | |
dc.contributor.author | Wong, Michelle M. Y. | |
dc.contributor.author | Port, Friedrich | |
dc.contributor.author | Combe, Christian | |
dc.contributor.author | Lopes, Antonio A. | |
dc.contributor.author | Reichel, Helmut | |
dc.contributor.author | Narita, Ichiei | |
dc.contributor.author | Stengel, Benedicte | |
dc.contributor.author | Robinson, Bruce M. | |
dc.contributor.author | Massy, Ziad | |
dc.contributor.author | Duttlinger, Christian | |
dc.date.accessioned | 2019-08-09T17:15:14Z | |
dc.date.available | WITHHELD_12_MONTHS | |
dc.date.available | 2019-08-09T17:15:14Z | |
dc.date.issued | 2019-07 | |
dc.identifier.citation | Pecoits‐filho, Roberto ; Fliser, Danilo; Tu, Charlotte; Zee, Jarcy; Bieber, Brian; Wong, Michelle M. Y.; Port, Friedrich; Combe, Christian; Lopes, Antonio A.; Reichel, Helmut; Narita, Ichiei; Stengel, Benedicte; Robinson, Bruce M.; Massy, Ziad; Duttlinger, Christian (2019). "Prescription of reninâ angiotensinâ aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care." The Journal of Clinical Hypertension 21(7): 991-1001. | |
dc.identifier.issn | 1524-6175 | |
dc.identifier.issn | 1751-7176 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/150590 | |
dc.description.abstract | Reninâ angiotensinâ aldosterone system inhibitors (RAASi) are recommended for chronic kidney disease (CKD) patients. In this study, we describe RAASi prescription patterns in the Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps) in Brazil, Germany, France, and the United States (US). 5870 patients (mean age 66â 72Â years; congestive heart failure [CHF] in 11%â 19%; diabetes in 43%â 54%; serum potassium â ¥5 in 20%â 35%) were included. RAASi prescription was more common in Germany (80%) and France (77%) than Brazil (66%) and the United States (52%), where the prevalence of prescription decreases particularly in patients with CKD stage 5. In the multivariable regression model, RAASi prescription was least common in the United States and more common in patients who were younger, had diabetes, hypertension, or less advanced CKD. In conclusion, RAASi prescription patterns vary by country, and by demographic and clinical characteristics. RAASi appear to be underused, even among patients with strong classâ specific recommendations. Although the reasons for this variation could not be fully identified in this crossâ sectional observation, our data indicate that the risk of hyperkalemia may contribute to the underuse of this class of agents in moderate to advanced CKD. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | chronic kidney disease | |
dc.subject.other | diabetes | |
dc.subject.other | heart failure | |
dc.subject.other | reninâ angiotensinâ aldosterone system inhibitors | |
dc.subject.other | albuminuria | |
dc.title | Prescription of reninâ angiotensinâ aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/150590/1/jch13563.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/150590/2/jch13563_am.pdf | |
dc.identifier.doi | 10.1111/jch.13563 | |
dc.identifier.source | The Journal of Clinical Hypertension | |
dc.identifier.citedreference | Ruggenenti P, Perna A, Remuzzi G. inhibitors to prevent endâ stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol. 2001; 12: 2832 â 2837. | |
dc.identifier.citedreference | Chang AR, Sang Y, Leddy J, et al. Antihypertensive medications and the prevalence of hyperkalemia in a large health system. Hypertension. 2016; 67 ( 6 ): 1181 â 1188. | |
dc.identifier.citedreference | Weir MR, Rolfe M. Potassium homeostatis and reninâ angiotensinâ aldosterone system inhibitors. Clin J Am Soc Nephrol. 2010; 5 ( 3 ): 531 â 548. | |
dc.identifier.citedreference | Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2016; 134: e282 â e293. | |
dc.identifier.citedreference | Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Workgroup. Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012; 2 ( 5 ): 337 â 414. | |
dc.identifier.citedreference | Skolnik N, Johnson EL. Clinical guidelines: ADA 2017 standards of medical care in diabetes. Family Practice News 2017. https://www.mdedge.com/familypracticenews/article/130408/diabetes/clinical-guidelines-ada-2017-standards-medical-care. Accessed 7/12/18. | |
dc.identifier.citedreference | Shafi T, Sozio SM, Luly J, et al; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators. Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices. Medicine (Baltimore). 2017; 96 ( 5 ): e5924. | |
dc.identifier.citedreference | Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of reninâ angiotensinâ aldosterone system inhibitors. Am J Manag Care. 2015; 21 ( 11 Suppl ): S212 â S220. | |
dc.identifier.citedreference | Palmer BF, Clegg DJ. Treatment of abnormalities of potassium homeostasis in CKD. Adv Chronic Kidney Dis. 2017; 24 ( 5 ): 319 â 324. | |
dc.identifier.citedreference | National Institutes of Health (NIH). ACHIEVE (aldosterone blockade for health improvement EValuation in endâ stage renal disease) Trial # NCT03020303. 2017. https://clinicaltrials.gov/ct2/show/NCT03020303. Accessed 7/12/18. | |
dc.identifier.citedreference | Kovesdy CP, Matsushita K, Sang Y, et al; for the CKD Prognosis Consortium. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis consortium metaâ analysis. Eur Heart J. 2018; 39: 1535 â 1542. | |
dc.identifier.citedreference | Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensinconvertingâ enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993; 329: 1456 â 1462. | |
dc.identifier.citedreference | Georgianos PI, Agarwal R. Revisiting RAAS blockade in CKD with newer potassiumâ binding drugs. Kidney Int. 2018; 93: 325 â 334. | |
dc.identifier.citedreference | Saran R, Robinson B, Abbott KC et al. US Renal Data System 2017 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2018; 71 ( 3 suppl 1 ): S1 â S672. | |
dc.identifier.citedreference | Ricardo AC, Roy JA, Tao K, et al. CRIC study investigators. Influence of nephrologist care on management and outcomes in adults with chronic kidney disease. J Gen Intern Med. 2016; 31 ( 1 ): 22 â 29. | |
dc.identifier.citedreference | Mariani L, Stengel B, Combe C, et al. The CKD outcomes and practice patterns study (CKDopps): rationale and methods. Am J Kidney Dis. 2016; 68 ( 3 ): 402 â 413. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.